Page 1 | Search Results | Diabetes Care | American Diabetes Association

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

Rena Pollack, Itamar Raz, Stephen D. Wiviott, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Ofri Mosenzon, Anna Maria Langkilde, Ingrid A.M. Gause-Nilsson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Marc S. Sabatine, Avivit Cahn

Diabetes Care 2023;46(1):156–164

https://doi.org/10.2337/dc22-1318

Published: 18 November 2022

View article titled, Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

Journal Articles

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Diabetes Care 2022;45(10):2350–2359

https://doi.org/10.2337/dc22-0382

Published: 23 August 2022

View article titled, Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Journal Articles

Association of Baseline HbA_1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz

Diabetes Care 2022;45(4):938–946

https://doi.org/10.2337/dc21-1744

Published: 11 January 2022

View article titled, Association of Baseline HbA<sub>1c</sub> With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Journal Articles

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

David D. Berg, Stephen D. Wiviott, Benjamin M. Scirica, Thomas A. Zelniker, Erica L. Goodrich, Petr Jarolim, Ofri Mosenzon, Avivit Cahn, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Per Johanson, Anna Maria Langkilde, Itamar Raz, Eugene Braunwald, Marc S. Sabatine, David A. Morrow

Diabetes Care 2021;44(11):2573–2581

https://doi.org/10.2337/dc21-1170

Published: 17 September 2021

View article titled, A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

Journal Articles

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Diabetes Care 2021;44(8):1805–1815

https://doi.org/10.2337/dc21-0076

Published: 11 August 2021

View article titled, The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Journal Articles

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Avivit Cahn, Itamar Raz, Lawrence A. Leiter, Ofri Mosenzon, Sabina A. Murphy, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott

Diabetes Care 2021;44(5):1159–1167

https://doi.org/10.2337/dc20-2492

Published: 02 March 2021

View article titled, Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Journal Articles

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

Avivit Cahn, Ofri Mosenzon, Stephen D. Wiviott, Aliza Rozenberg, Ilan Yanuv, Erica L. Goodrich, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz

Diabetes Care 2020;43(2):468–475

https://doi.org/10.2337/dc19-1476

Published: 16 December 2019

View article titled, Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

Includes: Supplementary data

Journal Articles

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease

Brian A. Bergmark, Deepak L. Bhatt, Eugene Braunwald, David A. Morrow, Ph. Gabriel Steg, Yared Gurmu, Avivit Cahn, Ofri Mosenzon, Itamar Raz, Erin Bohula, Benjamin M. Scirica

Diabetes Care 2018;41(3):577–585

https://doi.org/10.2337/dc17-1736

Published: 01 December 2017

View article titled, Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease

Includes: Supplementary data

Journal Articles

Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A_1c Targets? Diabetes Care 2016;38:e145–e146

Itamar Raz, Avivit Cahn

Diabetes Care 2016;39(12):e227

https://doi.org/10.2337/dc16-1428

Published: 10 November 2016

View article titled, Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A<sub>1c</sub> Targets? Diabetes Care 2016;38:e145–e146

Journal Articles

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Ofri Mosenzon, Gil Leibowitz, Deepak L. Bhatt, Avivit Cahn, Boaz Hirshberg, Cheryl Wei, KyungAh Im, Aliza Rozenberg, Ilan Yanuv, Christina Stahre, Kausik K. Ray, Nayyar Iqbal, Eugene Braunwald, Benjamin M. Scirica, Itamar Raz

Diabetes Care 2017;40(1):69–76

https://doi.org/10.2337/dc16-0621

Published: 17 October 2016

View article titled, Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Includes: Supplementary data

Journal Articles

Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS

Guntram Schernthaner, Avivit Cahn, Itamar Raz

Diabetes Care 2016;39(Supplement_2):S210–S218

https://doi.org/10.2337/dcS15-3009

Published: 16 July 2016

View article titled, Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS

Journal Articles

Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes

Avivit Cahn, William T. Cefalu

Diabetes Care 2016;39(Supplement_2):S137–S145

https://doi.org/10.2337/dcS15-3007

Published: 16 July 2016

View article titled, Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes

Journal Articles

Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial

Avivit Cahn, Itamar Raz, Ofri Mosenzon, Gil Leibowitz, Ilan Yanuv, Aliza Rozenberg, Nayyar Iqbal, Boaz Hirshberg, Mikaela Sjostrand, Christina Stahre, KyungAh Im, Estella Kanevsky, Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald

Diabetes Care 2016;39(8):1329–1337

https://doi.org/10.2337/dc15-2763

Published: 23 May 2016

View article titled, Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial

Includes: Supplementary data

Journal Articles

Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists

Avivit Cahn, Itamar Raz, Yosef Kleinman, Ran Balicer, Moshe Hoshen, Nicky Lieberman, Naomi Brenig, Stefano Del Prato, William T. Cefalu

Diabetes Care 2015;38(12):2293–2300

https://doi.org/10.2337/dc15-0187

Published: 30 October 2015

View article titled, Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists

Includes: Supplementary data

Journal Articles

Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial

Ofri Mosenzon, Cheryl Wei, Jaime Davidson, Benjamin M. Scirica, Ilan Yanuv, Aliza Rozenberg, Boaz Hirshberg, Avivit Cahn, Christina Stahre, Krzysztof Strojek, Deepak L. Bhatt, Itamar Raz

Diabetes Care 2015;38(11):2142–2150

https://doi.org/10.2337/dc15-1068

Published: 10 September 2015

View article titled, Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial

Journal Articles

Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial

Lawrence A. Leiter, Hwee Teoh, Eugene Braunwald, Ofri Mosenzon, Avivit Cahn, K.M. Prasanna Kumar, Alena Smahelova, Boaz Hirshberg, Christina Stahre, Robert Frederich, Francois Bonnici, Benjamin M. Scirica, Deepak L. Bhatt, Itamar Raz, for the SAVOR-TIMI 53 Steering Committee and Investigators

Diabetes Care 2015;38(6):1145–1153

https://doi.org/10.2337/dc14-2868

Published: 10 March 2015

View article titled, Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial

Includes: Supplementary data

Journal Articles

Targets for Body Fat, Blood Pressure, Lipids, and Glucose-Lowering Interventions in Healthy Older People

Constantine Tsigos, MD, PHD, Rafael Bitzur, MD, Yosef Kleinman, MD, Hofit Cohen, MD, Avivit Cahn, MD, Gianmaria Brambilla, MD, Giuseppe Mancia, MD, Guido Grassi, MD

Diabetes Care 2013;36(Supplement_2):S292–S300

https://doi.org/10.2337/dcS13-2021

Published: 17 July 2013

View article titled, Targets for Body Fat, Blood Pressure, Lipids, and Glucose-Lowering Interventions in Healthy Older People

NARROW

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Association of Baseline HbA_1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease

Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A_1c Targets? Diabetes Care 2016;38:e145–e146

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS

Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes

Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial

Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists

Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial

Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial

Targets for Body Fat, Blood Pressure, Lipids, and Glucose-Lowering Interventions in Healthy Older People

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only